Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants

3 Apr 2019

Abstract excerpt

Importance: Surgery currently offers the only chance for a cure in pancreatic ductal adenocarcinoma (PDAC), but it carries a significant morbidity and mortality risk and results in varying oncologic outcomes. At present, to our knowledge, there are no tests available before surgical resection to identify tumors with an aggressive biological phenotype that could guide personalized treatment strategies. Objective:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to Pancreatic and Hepatic Oncology Research
Share to Pancreatitis Pathology and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30942874
DOI: 10.1001/jamasurg.2019.0484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic VariantsPMID 30942874Read ↗

Prospective validation of a predictive non-invasive SNP-based biomarker signature in resectable pancreatic cancer: a study protocolSemantic proximity Read ↗

A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study.Semantic proximity Read ↗

Pancreatic Cancer: Genetics, Screening, Prevention, and Treatment.Semantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.Semantic proximity Read ↗

Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges.Semantic proximity Read ↗

Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium.Semantic proximity Read ↗

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Next-Generation Sequencing in Pancreatic CancerSemantic proximity Read ↗

A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.